Kenneth Galbraith compensation by year
Zymeworks Summary Compensation Table · all 4 fiscal years held| Component | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Salary | $582,481 | $625,452 | $654,833 | $656,763 |
| Bonus | $0 | $0 | $0 | $0 |
| Stock awards | $879,000 | $1,144,000 | $2,112,000 | $2,538,240 |
| Option awards | $5,044,999 | $1,194,627 | $1,985,672 | $2,366,565 |
| Non-equity incentive | $537,728 | $321,651 | $361,652 | $340,990 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $81,249 | $89,146 | $139,459 | $710,622 |
| Total | $7,125,457 | $3,374,876 | $5,253,616 | $6,613,180 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Zymeworks Inc. DEF 14A filed January 1, 1900, accession 0001193125-25-274338, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Zymeworks Inc. filed document, accession 0001193125-25-274338. Every figure is read from that document and cited to the page and table it appears in. Filed January 1, 1900.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 192,000 | $5,055,360 | — |
| RSU | 133,334 | $3,510,684 | — |
| RSU | 47,668 | $1,255,098 | — |
| Option | 288,000 | — | $13.22 |
| Option | 150,000 | — | $10.56 |
| Option | 53,750 | — | $8.00 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Zymeworks Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
23 Form 4 lines since the FY2024 proxy (filed January 1, 1900)current to 2026-11-06 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-01-12 | Grant or award derivative | — | 216,000 | $0.00 | 216,000 |
| 2026-01-12 | Grant or award derivative | — | 144,000 | $0.00 | 144,000 |
| 2026-01-12 | Exercise or conversion | — | 64,000 | $0.00 | 257,266 |
| 2026-01-12 | Exercise or conversion derivative | — | 64,000 | $0.00 | 128,000 |
| 2026-01-12 | Sale | — | 30,424 | $22.67 | 226,842 |
| 2026-01-12 | Grant or award derivative | — | 222,000 | $0.00 | 222,000 |
| 2026-01-05 | Exercise or conversion derivative | — | 47,668 | $0.00 | 0 |
| 2026-01-05 | Exercise or conversion | — | 66,666 | $0.00 | 224,952 |
The 8 most recent of 23 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Zymeworks discloses, by trigger · FY2024| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and resignation for good reason | — | $1,464,000 | — | — |
| Involuntary termination without cause | $655,000 | $1,464,000 | — | — |
| Disability | — | $5,787,690 | — | — |
| Death | — | $5,787,690 | — | — |
| Change in control and involuntary termination | $1,375,500 | $7,725,490 | — | — |
Per the Potential Payments Upon Termination or Change in Control table in Zymeworks Inc.'s FY2024 proxy. Estimates as the company printed them; a dash means it printed no figure.
Zymeworks’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Kenneth Galbraith · this page | Chief Executive Officer, President and Chair of Board of Directors | $5,253,616 |
| Leone Patterson | Executive Vice President, Chief Business Officer and Chief Financial Officer | $2,907,982 |
| CSO Paul A. Moore | Chief Scientific Officer | $1,986,803 |
Board service
Zymeworks board · FY2021–FY2025How this board is paid
Company policy: Zymeworks pays directors a $40,000 cash retainer. As stated in Zymeworks's FY2025 proxy.
The full Zymeworks compensation record
free company briefThis page is one person within Zymeworks's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Zymeworks proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Zymeworks's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Zymeworks's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order ZYME
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.